Beckman wins FDA nod for advanced test used in MI diagnosis

06/20/2013 | RTT News

The FDA has cleared Beckman Coulter, a unit of Danaher, to market its Access AccuTnI+3 troponin I test. The assay, which will run on the company's Access 2 immunoassay platform, has been shown in a clinical study to deliver precise as well as clinically sensitive and specific measurements to help doctors diagnose myocardial infarction.

View Full Article in:

RTT News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR
Director of Operations - GBS
Mayo Clinic
Rochester, MN